Paragate Medical Overview
Clinical-stage company offers a disruptive outpatient treatment solution addressing the top global healthcare cost driver: recurring admissions of congested Chronic Heart Failure patients. Our implanted, connected device removes excess fluid and salt and clears them to the patient’s bladder, providing continuous decongestion: personalized precise treatment with no patient involvement, out-of-hospital. Clinical trials are underway with strong results from an initial series of patients. Our target US market is 1.2M+ annual hospitalizations which generate $30B+ of hospital losses and payor costs, most of which are avoidable with our technology. ROW market is larger.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
2024 Winners| Jon DeHaan Foundation
Levron Medical, an Israeli medical device startup, has won first place at the Innovations in Cardiovascular Interventions (ICI) cardiology conference, securing the $200,000 John De-Haan Med-Tech Innovation Award. The company impressed judges with its Cardiac-Respiratory Physiological Assist (CPRA) technology, branded as Soulmate, which offers a novel treatment for heart failure by addressing both cardiac and respiratory challenges. The award highlights the companys innovative spirit and the potential of its technology to transform heart failure treatment. Levron Medicals success underscores its potential to set new standards in the field.
Product StageInvestment
TCT 2023 Shark Tank Innovation Competition: Highlights of Disruptive Innovative Technologies in Cardiovascular Medicine
growth-positive
Implantable device developed for remote care of heart and kidney failure patients
Paragate Medical, a portfolio company of NGT3 VC, has developed a remote, implantable solution for heart and kidney failure patients. Their IPUD device serves as a mechanical bypass of the kidneys, removing excess fluid from the body to keep patients balanced at home. The company has conducted successful preclinical studies and plans to begin clinical trials this year. Paragate Medical is part of NGT3, a venture capital firm focused on investing in life science start-ups led by Arab and Jewish entrepreneurs.
Investment
growth-positive
https://www.jpost.com/health-science/israeli-cardiac-device-aims-to-keep-heart-failure-patients-out-of-hospital-579322
Nazareth-based Paragate Medical has developed a fully-implantable medical device to prevent fluid overload caused by congestive heart failure and chronic kidney disease. The device aims to break the costly hospitalization cycle for heart failure patients and offers a 24/7 out-of-hospital solution. The company expects to commence clinical tests later this year in collaboration with leading cardiology specialist Prof. Piotr Ponikowsky. The device has already received backing from high-profile medical experts. Paragate is one of over a dozen life science and medical device start-ups working with Nazareth-based incubator NGT³.
Customers
growth-positive
Israeli cardiac devices dominate Shark Tank contest wins
Two Israeli startups, Enopace Biomedical and Paragate Medical, were finalists in a cardiovascular innovation competition. Enopace Biomedical won with its Harmony device, while Paragate Medical took third place with its implantable fluid removal device. Another Israeli company, Cognata, won an award for its use of artificial intelligence in autonomous vehicle testing. The startups success in these competitions indicates growth and recognition in the medical technology field. No specific investors or acquisition amounts are mentioned in the article. The event described in the article took place in 2017.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $10.64M |
| Last funding | $450K |
| Stage | Seed |
| Rounds | 6 |
| Investors | 2 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | paragate-medical.com |
Locations
Derech HaAtsma'ut 57, Haifa, Israel
Photos & Videos
2 item(s)
